Resources Repository
-
ReviewPublication 2015Major Concepts of Health Care Economics
This article provides a short simple guide to major economic concepts, such as supply, demand, monopoly, …
This article provides a short simple guide to major economic concepts, such as supply, demand, monopoly, monopsony, adverse selection, and moral hazard. Concepts are applied to central features of U.S. health care to illuminate some of the principal problems of health policy - high cost and the uninsured - and explain why solutions are difficult to obtain.
Benefit-Cost Analysis | Cost-Effectiveness Analysis | North America | Costing Methods | Health/Medicine -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Technology Assessment | Cost-Effectiveness Analysis | North America | Priority Setting/Ethics | Infectious Diseases | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Cost-Effectiveness Analysis | Middle East & North Africa | Global | Health Outcomes | Mathematical Models | Calibration/Validation | Infectious Diseases | Chronic Disease/Risk | Health Systems | Health/Medicine | Sub-Saharan Africa | Latin America & Caribbean | Asia & Pacific -
ReviewPublication 2006Public Health Policy for Cervical Cancer Prevention: Decision Science, Economic Evaluation, & Mathematical Modeling
Several factors are changing the landscape of cervical cancer control, including a better understanding of …
Several factors are changing the landscape of cervical cancer control, including a better understanding of the natural history of human papillomavirus (HPV), reliable assays for detecting high-risk HPV infections, and a soon to be available HPV-16/18 vaccine. There are important differences in the relevant policy questions for different settings. By synthesizing and integrating the best available data, the use of modeling in a decision analytic framework can identify those factors most likely to influence outcomes,…
Cost-Effectiveness Analysis | Decision Analysis | Global | Mathematical Models | Infectious Diseases | Chronic Disease/Risk | Economics/Finance | Health/Medicine | Science/Technology -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | North America | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2023Estimated Reductions in Opioid Overdose Deaths with Sustainment of Public Health Interventions in 4 U.S. States
This study utilizes a decision analytical model to simulate the opioid epidemic in four heavily …
This study utilizes a decision analytical model to simulate the opioid epidemic in four heavily impacted states: Kentucky, Massachusetts, New York, and Ohio. By analyzing the effects of increased initiation and retention of medications for opioid use disorder (MOUDs) and enhanced naloxone distribution over a 2 to 5-year timeframe, the research assesses the potential reduction in opioid overdose deaths (OODs). Results indicate that sustaining a combination of interventions could lead to substantial reductions in OODs,…
Decision Analysis | North America | Mathematical Models -
ArticlePublication 2023Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control …
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control in the US. A cost-effectiveness analysis was conducted using a Markov model based on the pharmacist-prescribing intervention used in The Alberta Clinical Trial in Optimizing Hypertension (or RxACTION). Outcomes included cardiovascular (CV) events, end-stage kidney disease events, life years, quality-adjusted life years (QALYs), lifetime costs, and lifetime incremental cost-effectiveness ratio (ICER). Costs were based on reimbursement rates, published literature, national…
Cost-Effectiveness Analysis | North America | Mathematical Models | State-Transition | Chronic Disease/Risk | Clinical Care | Health/Medicine -
ArticlePublication 2023Cost-Effectiveness of Intensive vs. Standard Blood Pressure Control Among Older Patients
This economic analysis explored the cost-effectiveness of intensive vs standard blood pressure control in older …
This economic analysis explored the cost-effectiveness of intensive vs standard blood pressure control in older hypertensive patients between 60 and 80 years in China, the US, and the UK. Treatment outcome data from the Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension (STEP trial) and different cardiovascular risk assessment models for a hypothetical cohort of STEP-eligible patients were used. Costs and utilities were obtained from published sources. A Markov model was used to…
Cost-Effectiveness Analysis | North America | Mathematical Models | Chronic Disease/Risk | Clinical Care -
ArticlePublication 2023Context-Specific Estimation of Future Unrelated Medical Costs and Their Impact on CEAs
This study developed and applied methods to estimate unrelated future medical costs (UFMC) for women …
This study developed and applied methods to estimate unrelated future medical costs (UFMC) for women with breast cancer in Israel and evaluated the impact of including UFMC in cost-effectiveness analyses (CEAs). Methods included a retrospective cohort study using 14 years of patient-level claims data from breast cancer patients and matched controls. UFMC were estimated through (a) the annual average all-cause healthcare costs of control subjects, and (b) predicted values from a generalized linear model (GLM)…
Cost-Effectiveness Analysis | Middle East & North Africa | Costing Methods | Health/Medicine